The U.S. Food and Drug Administration said on Friday it would take action against telehealth provider Hims & Hers
for its $49 weight-loss pill, including restricting access to the drug’s ingredients and referring the company to the Department of Justice for potential violations of federal law.
Federal action to limit the production of compounded drugs would be a win for Novo Nordisk
, which has been losing share in the weight-loss market to rival Eli Lilly
and telehealth firms like Hims. However, the FDA did not make clear whether it could quickly halt the sale of Hims’ product, the cheapest GLP-1 therapy on the U.S. market.
